Abstract

Herbal medicine represents an alternative for treating dyslipidemia. It has been probed that aerial part of *Eryngium heterophyllum*, a species of medicinal plant that belongs to the family Apiaceae, reduces cholesterol by 27% in rats. On the other hand, *Amphipterygium adstringens*, a Mexican tree exerts a significant hypocholesterolemic effect on rats, lowering cholesterol levels by 31%. The aim of this project was to evaluate the PC-300 tea (*Eryngium heterophyllum egelm + Amphipterygium adstringens*) against hypertriglyceridemia. It was a non-randomized, descriptive, prospective, longitudinal, and comparative clinical study. Voluntary subjects were assigned sequentially into two treatment groups: 1) fibrate (bezafibrate) 200 mg/day, and 2) PC-300 tea, one cup half an hour before eating. Baseline samples of serum total cholesterol and triglycerides were obtained and measured again after 1 month of treatment. There were 17 patients (males: 6, females: 11) treated with the tea, with a mean age of 49 ± 15 years, and 17 patients (males: 8, females: 9) treated with bezafibrate, with a mean age of 44.7 ± 13 years. In the first group, the percentage of triglyceride reduction was 19.7% ($p \leq 0.05$), while in the second group, this was 44.8% ($p \leq 0.001$). We conclude that consumption of PC-300 reduces triglyceride levels an average of 20% after 1 month.

Keywords: *Amphipterygium adstringens*, *Eryngium heterophyllum egelm*; Hypertriglyceridemia; PC-300
Introduction
Cardiovascular diseases are the leading cause of death worldwide. Among the major risk factors for this health problem, dyslipidemia is highlighted, being the hypertriglyceridemia the most common dyslipidemia in Mexico. Of particular concern, the treatments available for these conditions, while controlling the disease, are accompanied by a number of adverse effects, in addition to the high cost of some of these treatments, which generate long-term treatment dropout. Therefore, the search for novel treatment alternatives is necessary. Herbal medicine represents an alternative for treating dyslipidemia. Among the options, Chinese groups have tested several composites with one or more plant extracts [1-3]. Unfortunately, the majority of these studies have been conducted in animals. Paradoxically, despite being one of the countries with more biodiversity and with millennial use of medicinal plants, Mexico has published a relatively few clinical scientific papers related with this topic [4,5]. Speaking about successful experiences with herbal medicine, the PC-300 tea (Eryngium heterophyllum and Amphipterygium adstringens) (Figure 1), developed at the University of Chapingo, State of Mexico, Mexico, has the potential to reduce cholesterol and triglycerides [6,7]. Eryngium heterophyllum is a species of medicinal plant native to Mexico that belongs to the family Apiaceae; it was previously known that the aerial part of E. heterophyllum reduces cholesterol by 27% in rats [8]; even more so, E. heterophyllum possesses anti-inflammatory properties [9]. On the other hand, A. adstringens, a Mexican tree known as cuachalalate, exerts a significant hypocholesterolemic effect on rats, lowering cholesterol levels by 31% [10]. The purpose of this study was to verify the effectiveness of the PC-300 tea compared with bezafibrate in the clinical field.

Methods
Place and subjects
It is a descriptive, prospective, longitudinal, and comparative clinical study with ClinicalTrials.gov identifier of NCT03649269 developed at Ciprés Grupo Médico S.C. (CGM), Toluca, Mexico, from January 2014 to December 2014. Patients with hypertriglyceridemia, aged >18 years and with an educational level at least of primary school were invited to participate in the study. Patients with hepatic disease were excluded, and those missing an appointment during the study were discarded from the final analysis. Voluntary subjects were assigned

Figure 1. PC-300 tea presentation
sequentially into two treatment groups: 1) fibrate (bezafibrate) 200 mg/day, and 2) PC-300 tea, one cup half an hour before eating.

Plants selection
The collected plants were cultured in Texcoco, State of Mexico and classified and authenticated by Dr. Erick Estrada Lugo, of the Autonomous University of Chapingo, Mexico. The PC-300 is made with the aerial part of the *E. heterophyllum* and with the bark of the tree *A. adstringens*. The full sterile bottle weights 240 g and the percentage of grams per bottle of each species is 50%.

Tea prescription
The indicated steps for the use of the tea were: put a cup of water to boil, then add a small spoon of tea and let it simmer 4 minutes. Once this is done, it is strained and it can be taken 15 to 20 minutes before breakfast, lunch and dinner.

Sample
To obtain a 90% statistical power with an alpha error of 0.05 (two-sided test), to demonstrate an effect of a 15% reduction in TG level in patients when received PC-300, 17 patients were needed per group.

Blood samples
Blood samples (5-ml) were taken after an 8–12-h fasting period in Vacutainer™ tubes. Serum samples were analyzed for cholesterol (mg/dl), triglycerides (mg/dl) and glucose (mg/dl), using appropriate kits (Randox Laboratories Ltd., U.K.) (Vitalab Selectra II, Vital Scientific, The Netherlands). Sampling times were at baseline and after 1 month with either of the two treatments. All tests were measured according to standardized procedures recommended by the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) at Laboratorio Artemisa, Toluca, Mexico.

Anthropometric measures
Patients were measured (m) and weighed (kg) (Obi, México). Body mass index (BMI) was calculated as weight (kg) divided by height (m) squared. Blood pressure was measured with a calibrated sphygmomanometer (Welch Allyn, USA) after 5 min of rest.

Diet
All of the patients were given a low lipid diet. Calculated kcal were based on ideal weight minus 200 kcal/day if overweight.

Statistics
Results were expressed as mean ± Standard deviation (SD). Differences between initial vs. final values were compared with the Mann-Whitney test. The normality hypothesis was tested using the Kolmogorov-Smirnov test. A $p$ value of <0.05 was considered significant. All tests were performed through the SPSS ver. 23 statistical software.

Ethics
The Ethical and Research Committee of Ciprés Grupo Médico S.C. (CGM), code 2014/02, approved this study. The procedures followed were in accordance with the
Results
There were 17 patients in the group treated with PC-300 tea, mean age 49 ± 15.9 years (females: 11, males: 6), and 17 were treated with bezafibrate (9 females and 8 males), mean age 44.7 ± 13 years. We had 12 dropouts: seven with the tea, and five with bezafibrate.
In the first group, the percentage of triglyceride reduction was 19.7% (p ≤0.05), while in the second group, this was 44.8% (p ≤ 0.01). In relation to cholesterol, the reduction percentages were 4.8% (p ≤ 0.05) and 9.2%, respectively (Table 1).
In the first group, 15 (88.23%) patients had diminished triglyceride levels and two (11.76%) exhibited increased levels. In the second group, the numbers for these changes were 16 (94.11%) and one (5.88%), respectively. With respect to cholesterol, nine patients (52.94%) had reduced levels (these same patients demonstrated reduced triglycerides) with the PC-300 tea; in comparison, 13 patients (76.47%) showed this response with bezafibrate.
Regarding gender, in the PC-300 tea group, five males (83.33%) and 10 females (90.90%) had reduced triglyceride levels. Similarly, in the fibrate group, these percentages were 80 and 100%, respectively.

Table 1. Lipid, glucose and BMI comparison after one month of treatment

<table>
<thead>
<tr>
<th>Group</th>
<th>Tea</th>
<th>Bezafibrate</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Initial</td>
<td>After one month</td>
<td>Initial</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>27.2 ± 4.2</td>
<td>27.3 ± 4.1</td>
<td>27.2 ± 3.8</td>
</tr>
<tr>
<td>Cholesterol (mg/dl)</td>
<td>212.2 ± 35.5</td>
<td>200.9 ± 31.9</td>
<td>221.5 ± 59</td>
</tr>
<tr>
<td>Triglycerides (mg/dl)</td>
<td>293.8 ± 142.3</td>
<td>216.3 ± 117.7</td>
<td>367.5 ± 141.9</td>
</tr>
<tr>
<td>Glucose (mg/dl)</td>
<td>170 ± 93.5</td>
<td>121.7 ± 28.2</td>
<td>133.3 ± 80.5</td>
</tr>
</tbody>
</table>

BMI: Body Mass Index. a: in the tea group, b: in the bezafibrate group. * p<0.05, **p<0.001 compared to initial value.

Discussion
Using herbal alternatives to treat dyslipidemia is not new. For example, Kurian et al. published that the G-400 polyherbal drug (Salacia oblonga root, Tinospora cordifolia stem, Emblica offinalis Gaertn, Curcuma longa, and Gymnema sylvestre) acts as a hypolipidemic agent in patients with diabetes and also attenuates hyperglycemia [11].
In the study of *E. heterophyllum* by Miranda Velásquez [7] the results of chemical reactions for the detection of secondary metabolites suggested the presence of the following types of compounds: alkaloids in the aqueous extract, coumarins only in the aqueous and methanol extract and phenolic hydroxyl (except ethanolic and methanolic extracts) in aqueous extract.

Among other components found in the extracts of *E. heterophyllum*, the reduction of serum concentrations of lipids has been explained by the action of saponins [8].

In our study, regardless of treatment type, there was a reduction in triglyceride levels, but the percentage of reduction of triglycerides was higher with the fibrate (44.8% ± 23.5) than with the PC-300 tea (19.7% ± 40.6). Notwithstanding this, supplements with PC-300 not only reduced triglycerides, but also total cholesterol.

Liu ZL et al reported an analysis of three randomized trials with 170 participants, evaluating Chinese herbal medicines to treat alone or in combination with gemfibrozil hypertriglyceridemia. All three trials reported results in favor of the herbal treatment [12]. In general, China is performing a world leadership novel research based on herbal medicine to lower lipids [13,14]. Mexico, with its millennial use of herbology could follow the same trend.

Current treatment strategies directed towards dyslipidemia tend to be limited due to expensive cost of research and sale [15]. By contrast, new insights suggest benefits of natural agents as treatments for metabolic syndrome [16-19]. Following this line, *Eryngium heterophyllum* as well as *Amphipterygium adstringens* can be purchased from local markets, but to make it easier, the mix presentation is already prepared and is affordable, economically speaking for low-income populations.

In summary, consumption of PC-300 tea showed a trend primarily in reducing triglyceride levels; however, there is great variability in the percentage of decrease among patients, which could be due to poor treatment adherence and to the different type of dyslipidemia. With this information we postulate that use of the PC-300 tea may be recommended as a monotherapy or in combination with drugs, depending on the degree of lipid increase, age and comorbidities. Specifically, PC-300 should be prescribed for 20–30% above normal triglyceride values. Of course, when taking the tea there are some side effects, being the main two a decreased consistency of the stools and even diarrhea if taken almost immediately previous to the food ingestion.

A limitation of the study is the low number of patients; this is explained in part due to the withdrawal of Bezalip™ (Roche) (bezafibrate) from the Mexican market, the drug with which we began medical treatment in one of the groups. However, a clear advantage of the PC-300 tea is its cost and the absence of collateral effects. The price of a bottle of 150 g of PC-300 tea is of 6.5 US $ and lasts three months, this mean a cost of 2.1 US $ per month. By contrast, the monthly cost with Bezalip (bezafibrate) is of 24.6 US $,
with Controlip (fenofibrate) is 35.3 US $ and with Lopid (gemfibrozil) it is 48.4 US $. We can conclude that the PC-300 tea can contribute to the lipid profile control with a reduction in the TG levels by about 30% within one month after beginning this treatment. Further study should be conducted on the long-term effect of the tea tested on larger populations.

**Funding**
This work was partially funded by Ciprés Grupo Médico S.C. (CGM).

**Conflicts of Interest**
None.

**Acknowledgment**
None.

**References**


